Inventor · disambiguated record
Marcos Milla
Also filed as: MILLA MARCOS · MILLA MARCOS E
11 granted patents·16 pending applications·59 citations·filing 2018–2025
88Inventor score
Top patents by PatentIndex Score
27 records- 0196US11077195B2IL-2 conjugates and methods of use thereofSYNTHORX INC·Filed 2020·Granted Aug 3, 2021·11 cites·33 claims
- 0296US10610571B2Cytokine conjugates for the treatment of proliferative and infectious diseasesSYNTHORX INC·Filed 2019·Granted Apr 7, 2020·30 cites·30 claims
- 0395US11701407B2Cytokine conjugates for the treatment of proliferative and infectious diseasesSYNTHORX INC·Filed 2020·Granted Jul 18, 2023·7 cites·28 claims
- 0495US11622993B2Cytokine conjugates for the treatment of autoimmune diseasesSYNTHORX INC·Filed 2018·Granted Apr 11, 2023·9 cites·19 claims
- 0593US12377131B2Cytokine conjugates for the treatment of autoimmune diseasesSYNTHORX INC·Filed 2023·Granted Aug 5, 2025·1 cites·23 claims
- 0685US12318431B2Cytokine conjugates for the treatment of proliferative and infectious diseasesSYNTHORX INC·Filed 2023·Granted Jun 3, 2025·0 cites·21 claims
- 0785US2025325633A1Cytokine conjugates for the treatment of autoimmune diseasesSYNTHORX INC·Filed 2025·Application pending·0 cites
- 0875US2025154218A1IL-2 Conjugates and Methods of Use to Treat Autoimmune DiseasesSYNTHORX INC·Filed 2024·Application pending·0 cites
- 0974US2024383957A1IL-15 Conjugates and Uses ThereofSYNTHORX INC·Filed 2024·Application pending·0 cites
- 1074US2025325632A1Cytokine conjugates for the treatment of proliferative and infectious diseasesSYNTHORX INC·Filed 2025·Application pending·0 cites
- 1173US2024287151A1IL-15 Conjugates and Uses ThereofSYNTHORX INC·Filed 2024·Application pending·0 cites
- 1269US2024245792A1Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumabSYNTHORX INC·Filed 2023·Application pending·0 cites
- 1369US2024226309A1Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximabSYNTHORX INC·Filed 2023·Application pending·0 cites
- 1466US11919934B2IL-15 conjugates and uses thereofSYNTHORX INC·Filed 2020·Granted Mar 5, 2024·0 cites·21 claims
- 1566US11390921B2Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)ADAPTIVE BIOTECHNOLOGIES CORP·Filed 2018·Granted Jul 19, 2022·1 cites·10 claims
- 1664US2023416327A1Immuno oncology therapies with il-2 conjugatesSYNTHORX INC·Filed 2023·Application pending·0 cites
- 1763US2023277627A1Immuno oncology combination therapy with il-2 conjugates and pembrolizumabSYNTHORX INC·Filed 2023·Application pending·0 cites
- 1862US12344648B2IL-15 conjugates and uses thereofSYNTHORX INC·Filed 2020·Granted Jul 1, 2025·0 cites·33 claims
- 1962US12234271B2Il-2 conjugates and methods of use to treat autoimmune diseasesSYNTHORX INC·Filed 2020·Granted Feb 25, 2025·0 cites·57 claims
- 2062US2020246467A1Il-2 conjugates and methods of use thereofSYNTHORX INC·Filed 2020·Application pending·0 cites
- 2159US2022273767A1Interleukin 10 Conjugates and Uses ThereofSYNTHORX INC·Filed 2022·Application pending·0 cites
- 2258US2025302950A1Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumabSYNTHORX INC·Filed 2022·Application pending·0 cites
- 2357US12491254B2Interleukin 10 conjugates and uses thereofSYNTHORX INC·Filed 2021·Granted Dec 9, 2025·0 cites·18 claims
- 2457US2023042101A1Determining WT-1-Specific T Cells and WT-1 Specific T Cell Receptors (TCRS)ADAPTIVE BIOTECHNOLOGIES CORP·Filed 2022·Application pending·0 cites
- 2555US2025075276A1Methods for selecting subjects and treating cancer with il-2 therapySYNTHORX INC·Filed 2023·Application pending·0 cites
- 2650US2021046160A1Immuno Oncology Combination Therapies With IL-2 ConjugatesSYNTHORX INC·Filed 2020·Application pending·0 cites
- 2748US2022016252A1Immuno oncology combination therapy with il-2 conjugates and anti-egfr antibodiesSYNTHORX INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Marcos Milla files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →